The Philadelphia HIV Therapeutic and Prevention Clinical Trials Unit (Philadelphia HIV CTU-PHCTU) will provide the administrative infrastructure and scientific leadership to advance the science of HIV treatment and prevention within the five proposed HIV Research Networks, Adult Therapeutics, Therapeutics in Pediatric and Maternal Populations, Integrated Prevention, Vaccines, and Microbicides through four specific research aims:
Specific Aim 1. Participate in the creation and implementation of the scientific agenda of the HIV Research Networks through committee and protocol team membership and through initiation of new Network science.
Specific Aim 2. Participate in the implementation of the scientific agenda of the HIV Research Networks through the cost efficient conduct of clinical trials.
Specific Aim 3. Train and mentor the next generation of HIV investigators. By engaging fellows and junior faculty in protocol development, educational conferences and clinical trials, the PHCTU will actively recruit and train the next generation of HIV investigators.
Specific Aim 4. Educate the Philadelphia medical, scientific and HIV-affected communities about advances in HIV therapy and prevention. The Philadelphia HIV CTU will help to coordinate and advertise the HIV-related medical and scientific forums that currently exist, and will continue to seek input from the HIV-affected community through its Community Advisory Board and through educational outreach to HIV affected groups. The Philadelphia HIV CTU will feature an integrated, efficient clinical trials structure with four clinical research sites, three on the University of Pennsylvania (University of Pennsylvania Perelman School of Medicine-PSOM and The Children's Hospital of Philadelphia- CHOP) medical campus and one on the Drexel University medical campus, including two sites that will focus on adult HIV therapeutic trials, one that will focus on adult prevention trials, and one that will focus on trials involving pediatric ad adolescent populations.

Public Health Relevance

Despite numerous advances in the understanding of HIV pathogenesis, the realization of effective antiretroviral therapy (ART), and the widening scope of HIV prevention strategies, many challenges remain in the domains of HIV treatment and prevention that will need to be studied in adult, adolescent, and pediatric populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1AI069534-08
Application #
8609631
Study Section
Special Emphasis Panel (ZAI1-RB-A (S2))
Program Officer
Castillo, Blanca E
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2013-12-10
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$1,851,433
Indirect Cost
$716,870
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Jacobson, Jeffrey M; Zheng, Lu; Wilson, Cara C et al. (2016) The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 71:163-71
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Sawinski, Deirdre; Forde, Kimberly A; Eddinger, Kevin et al. (2015) Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients. Kidney Int 88:341-9
Gowda, Charitha; McKittrick, Noah; Kim, Deborah et al. (2015) Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. AIDS Res Treat 2015:653840
Longenecker, Chris T; Kitch, Douglas; Sax, Paul E et al. (2015) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69:168-77
Taiwo, Babafemi O; Chan, Ellen S; Fichtenbaum, Carl J et al. (2015) Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis 61:1179-88
Tebas, Pablo; Spitsin, Sergei; Barrett, Jeffrey S et al. (2015) Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS 29:931-9
Morrow, Matthew P; Tebas, Pablo; Yan, Jian et al. (2015) Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther 23:591-601

Showing the most recent 10 out of 38 publications